日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer

奥拉帕尼联合度伐利尤单抗治疗转移性去势抵抗性前列腺癌患者的II期研究

Li, Chennan; Madan, Ravi A; Lee, Min-Jung; Lee, Sunmin; Sato, Nahoko; Rastogi, Shraddha; Shrestha, Roshan; Aragon-Ching, Jeanny B; Goswami, Meghali; Donahue, Renee N; Cordes, Lisa M; Baj, Anna; Seo, Clara C Y; Terrigino, Nicholas T; Bright, John R; Hennigan, S Thomas; King, Isaiah M; Trostel, Shana Y; Fenimore, John M; Liu, Yi; Calzone, Kathleen A; Schlom, Jeffrey; Gulley, James L; Dahut, William L; Figg, William D; Sowalsky, Adam G; Lee, Jung-Min; Karzai, Fatima

Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities

门诊化疗相关毒性反应导致急诊就诊风险因素的真实世界数据

Karovic, Sanja; Dvergsten, Erik; Pierattini, Chiara; Barac, Ana; Fay, Lauren; Cannon, Timothy L; Harnden, Kathleen K; Aragon-Ching, Jeanny B; Cuevo, Raymund S; Maitland, Michael L; Deeken, John F

How to choose duration of additional androgen deprivation therapy with salvage radiation therapy: short, long, more, or none?

如何选择在挽救性放射治疗中进行额外雄激素剥夺治疗的持续时间:短期、长期、更多还是不进行治疗?

Aragon-Ching, Jeanny B

The role of circulating tumor DNA (ctDNA) in urothelial cancers

循环肿瘤DNA(ctDNA)在尿路上皮癌中的作用

Aragon-Ching, Jeanny B

Polygenic risk score (PRS) as prostate cancer screening: ready for primetime?

多基因风险评分(PRS)作为前列腺癌筛查手段:准备好迎接黄金时代了吗?

Park, Jinny; Aragon-Ching, Jeanny B

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

索拉非尼治疗雄激素非依赖性前列腺癌的 II 期临床试验

William L Dahut, Charity Scripture, Edwin Posadas, Lokesh Jain, James L Gulley, Philip M Arlen, John J Wright, Yunkai Yu, Liang Cao, Seth M Steinberg, Jeanny B Aragon-Ching, Jürgen Venitz, Elizabeth Jones, Clara C Chen, William D Figg

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

在 ARAMIS 研究中,达罗鲁胺治疗非转移性去势抵抗性前列腺癌的长期安全性和耐受性以及不良事件发生时间进程

Shore, Neal D; Gratzke, Christian; Feyerabend, Susan; Werbrouck, Patrick; Carles, Joan; Vjaters, Egils; Tammela, Teuvo L J; Morris, David; Aragon-Ching, Jeanny B; Concepcion, Raoul S; Emmenegger, Urban; Fleshner, Neil; Grabbert, Markus; Lietuvietis, Vilnis; Mahammedi, Hakim; Cruz, Felipe M; Paula, Adriano; Pieczonka, Christopher; Rannikko, Antti; Richardet, Martin; Silveira, Glauco; Kuss, Iris; Le Berre, Marie-Aude; Verholen, Frank; Sarapohja, Toni; Smith, Matthew R; Fizazi, Karim

Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients

在EMBARK和PSMA PET成像技术应用时代,生化复发性前列腺癌:一切都变了,唯独患者变了。

Einstein, David J; Aragon-Ching, Jeanny B; Karzai, Fatima; Madan, Ravi A

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer

转移性激素敏感性前列腺癌治疗格局的快速演变

Yu, Eun-Mi; Patel, Ishan; Hwang, Min Woo; Polani, Faran; Aragon-Ching, Jeanny B

Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial

在 JAVELIN Bladder 100 试验中完善亚组分析和确定最佳患者人群

Aragon-Ching, Jeanny B